About
Alan joined Sofinnova as a Partner in 2017. He focuses on clinical-stage product companies, particularly in oncology, rare diseases and other specialty therapeutic areas. He currently serves on the boards of Dimension Therapeutics, Inc., Principia Biopharma, and Human Longevity, Inc. Before joining Sofinnova, Alan held executive management and board of director positions at numerous companies in the biotechnology sector. Most recently he was Executive Vice President at Celgene Corporation, and prior to that held positions of President for Celgene’s Europe, Mid-East, and Africa regions as well as Senior Vice President of Global Medical Affairs. Previously, Alan was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. Before becoming CEO at Gloucester Pharmaceuticals he was President, Oncology for Geron Corporation and was Chief Medical Office of Threshold Pharmaceuticals. Prior to that, Alan held numerous positions of increasing resp
Position in the VCSift Database
- • 8 investors at Matrix Capital Management are tracked.
- • 1,801 investors hold the Managing Director role in VCSift. Alan Colowick is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like Alan
Search Investors